Status:
COMPLETED
The TOGETHER Project - Liver
Lead Sponsor:
Mayo Clinic
Conditions:
Liver Transplant Rejection
Eligibility:
All Genders
18+ years
Brief Summary
To validate the use of a RNAseq-based peripheral blood assay in liver transplant recipients when correlated to liver biopsy results.
Detailed Description
The study is a prospective, observational study utilizing peripheral blood assays that will be collected at time points that are considered standard of care at most institutions. 100 participants will...
Eligibility Criteria
Inclusion
- Patients who have given informed consent and are willing to comply with the protocol, including the use of their peripheral blood specimens and data for subsequent research.
- Patients with increased risk of rejection. Patients must meet at least one of the following criteria:
- Autoimmune etiology of the original liver disease (autoimmune hepatitis, primary biliary cirrhosis or primary sclerosing cholangitis)
- Recipients of donation-after-cardiac death (DCD) donors
- Recipients of simultaneous liver-kidney transplantation
- Positive crossmatch liver transplant (T cell flow crossmatch or B cell flow crossmatch).
Exclusion
- Adult ( ≥ = 18 years) renal transplant recipient.
Key Trial Info
Start Date :
March 15 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2020
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT03874286
Start Date
March 15 2017
End Date
April 30 2020
Last Update
May 20 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Phoenix, Arizona, United States, 85054
2
Mayo Clinic
Jacksonville, Florida, United States, 32224
3
Mayo Clinic
Rochester, Minnesota, United States, 55905